Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with multiple myeloma (a type of blood cancer), confirmed through a bone marrow test, using standard international diagnostic guidelines.
- Your multiple myeloma has come back or stopped responding to treatment after trying 2 to 4 previous rounds of therapy.
- You are 18 years of age or older.
- You are willing to sign a consent form, take part in the study, and provide relevant medical samples and health updates over time.
Who may not be able to join:
- You still have side effects from previous cancer treatment that have not returned to normal or near-normal levels.
- You have another active cancer or a serious ongoing illness, such as significant heart, brain, liver, or kidney problems, that could affect how you respond to the treatment or the study results.
- You have had a bone marrow transplant or certain other treatments that could affect your bone marrow or immune system within the last 6 months before the study starts.
- You have a known allergy or serious allergic reaction to either of the study drugs (selinexor or ixazomib) or any of their ingredients.
- You have a known HIV infection.
- You have taken part in another clinical trial within the last 30 days, or plan to do so during this study.
- You are currently pregnant or breastfeeding.
- You have a psychiatric condition or any other reason that would make it difficult to follow the study's requirements.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 156-13485304136
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To evaluate the overall response rate (ORR) after two cycles of selinexor-based therapy.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.